Drug Profile
Research programme: tuberculosis therapeutics - Shreya Life Sciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Shreya Life Sciences
- Developer National Institute of Oceanography; Shreya Life Sciences
- Class Antituberculars
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Tuberculosis in India (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Tuberculosis in India
- 25 Jul 2016 Preclinical trials in Tuberculosis in India (unspecified route)